San Francisco, California– (Newsfile Corp. – December 25, 2024) – On December 9, 2024, just a few months after making an initial public offering in September 2024, BioAge Labs, Inc.NADAQ: BIOA) made the surprise announcement that it is abandoning a Phase 2 study of its lead product, azelaprag, intended to treat metabolic diseases such as obesity.
Hagens Berman has opened an investigation and urges investors in BioAge who bought shares in the company's IPO or in the open market and suffered large losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/bioa
Contact the firm now: BIOA@hbsslaw.com
844-916-0895
BioAge Research, Inc. (BIOA):
The investigation focused on the validity of BioAge's disclosures about safety data and other issues related to azelaprag, which the company said in its IPO documents was “well tolerated in 265 people in a Phase 1 clinical trial.”
BioAge's announcement came into question after the sale was closed on December 6, 2024, when the company announced the discontinuation of the STRIDES Phase 2 clinical trial to test azelaprag in combination with tirzepatide in the treatment of obesity. BioAge said liver transaminitis was seen in patients receiving azelaprag.
The news sent BioAge's stock price down nearly 80% on December 9, 2024.
“We believe BioAge was not transparent with investors about the safety profile of azelaprag before the December 6 announcement,” said Reed Kathrein, the Hagens Berman partner who led the investigation.
If you invested in BioAge and have a large loss, or have information that could help the firm's investigation, submit your loss now »
If you would like more information and answers to frequently asked questions about BioAge research, read more »
Whistles: Individuals with non-public information about BioAge should consider their options to assist in the investigation or take advantage of the SEC Whistleblower program. Under the new program, analysts who provide advance information can receive compensation of up to 30 percent of any successful returns made by the SEC. For more information, call Reed Kathrein here 844-916-0895 or email BIOA@hbsslaw.com.
###
About Hagens Berman
Hagens Berman is a global plaintiffs' rights firm that focuses on accountability. The firm is home to a strong practice and represents investors as well as claimants, employees, customers and others in cases that achieve real results for those harmed by corporate negligence and other wrongdoing. Hagens Berman's team has defended over $2.9 billion in this area of law. More about the firm and its achievements can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
To view the source of this document, please visit https://www.newsfilecorp.com/release/235182